Loading the page…
Nasdaq 100
GILD
Gilead Sciences, Inc., Health Care
$170.68
+3.06% on the day
Close of Fri, Oct 30, 2026
+210.7% over 5Y
2021-11-012024-05-012026-10-30
Nasdaq 100
Gilead Sciences, Inc., Health Care
$170.68
+3.06% on the day
Close of Fri, Oct 30, 2026
| Quarter ending | Jun 2026 | Mar 2026 | Dec 2025* | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024* | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8B | $7.0B | $7.9B | $7.8B | $7.1B | $6.7B | $7.6B | $7.5B |
| Gross margin | 79.8% | 79.2% | 79.5% | 79.8% | 78.8% | 76.9% | 79.1% | 79.1% |
| Operating margin | -133.2% | 37.2% | 25.0% | 42.8% | 34.9% | 33.6% | 32.4% | 11.8% |
| Net margin | -134.5% | 29.0% | 27.5% | 39.3% | 27.7% | 19.7% | 23.6% | 16.6% |
| EPS, diluted | −$8.45 | $1.61 | $1.75 | $2.43 | $1.56 | $1.04 | $1.43 | $1.00 |
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
| Measure | GILD | Higher than |
|---|---|---|
| Earnings yield (earnings ÷ price) | -1.5% | 5% |
| Book yield (book value ÷ price) | 5.6% | 21% |
| Free cash flow yield | 4.5% | 69% |
| Buyback yield | 0.9% | 51% |
| Revenue growth, a year | 2.4% | 14% |
| EPS growth, a year | 1684.2% | 99% |
| Return on equity | -27.4% | 4% |
| Return on assets | -6.6% | 3% |
| Net margin | -10.6% |
Research
Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
| 6% |
| Liabilities ÷ assets | 76.0% | 86% |
|---|
| Past year, skipping last month | 27.5% | 68% |
|---|
| Past 6 months, skipping last month | 13.4% | 67% |
|---|
| Volatility, a year's worth | 26.6% | 22% |
|---|
"Higher than" is the share of the 100 with a lower figure. Financial figures from SEC filings, market figures from daily closes. Dividend yield and beta are under Valuation below.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
From Yahoo Finance, gilead.com
GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loomStockStory, 22h ago
How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A DecadeInvestor's Business Daily, Oct 30
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor ConferencesBusiness Wire, Oct 30
What Just Happened To Alnylam Stock?Trefis, Oct 30
Gilead's HIV Franchise Supports Growth Outlook, RBC SaysMT Newswires, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loomStockStory, 22h agoHow Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A DecadeInvestor's Business Daily, Oct 30Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor ConferencesBusiness Wire, Oct 30What Just Happened To Alnylam Stock?Trefis, Oct 30Gilead's HIV Franchise Supports Growth Outlook, RBC SaysMT Newswires, Oct 30
Gilead (GILD) Q3 2026 Earnings Call TranscriptMotley Fool, Oct 30
GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthZacks, Oct 30UBS Adjusts Gilead Sciences Price Target to $195 From $175, Maintains Buy RatingMT Newswires, Oct 30Needham Adjusts Price Target on Gilead Sciences to $200 From $170MT Newswires, Oct 30Leerink Partners Adjusts Price Target on Gilead Sciences to $145 From $129MT Newswires, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
Every transaction, in AdvancedSEC Form 4, public domain. The latest 40 of 83 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Dickinson Andrew DCFO | Sold on the market10b5-1 plan | −3,000 | $156.22 | $469K | Form 4 ↗ |
| Oct 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sold on the market10b5-1 plan | −3,000 | $156.22 | $469K | Form 4 ↗ |
| Oct 1, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Sold on the market10b5-1 plan | −15,000 | $147.90average | $2.2M | Form 4 ↗ |
| Sep 22, 2026 | Burkhart ErinSVP, Controllership | Units vested | +2,223 | — | — | Form 4 ↗ |
| Sep 22, 2026 | Burkhart ErinSVP, Controllership | Tax withholding | −768 | $152.67 | $117K | Form 4 ↗ |
| Sep 15, 2026 | Dickinson Andrew DCFO | Sold on the market10b5-1 plan | −3,000 | $145.29 | $436K | Form 4 ↗ |
| Sep 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sold on the market10b5-1 plan | −3,000 | $144.22average | $433K | Form 4 ↗ |
| Sep 10, 2026 | Dickinson Andrew DCFO | Units vested | +2,797 | — | — | Form 4 ↗ |
| Sep 10, 2026 | Dickinson Andrew DCFO | Tax withholding | −1,347 | $144.81 | $195K | Form 4 ↗ |
| Sep 10, 2026 | Berger DietmarChief Medical Officer | Units vested | +533 | — | — | Form 4 ↗ |
| Sep 10, 2026 | Berger DietmarChief Medical Officer | Tax withholding | −263 | $144.81 | $38.1K | Form 4 ↗ |
| Sep 10, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Units vested | +2,797 | — | — | Form 4 ↗ |
| Sep 10, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Tax withholding | −1,347 | $144.81 | $195K | Form 4 ↗ |
| Sep 10, 2026 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Units vested | +590 | — | — | Form 4 ↗ |
| Sep 10, 2026 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Tax withholding | −285 | $144.81 | $41.3K | Form 4 ↗ |
| Sep 10, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Units vested | +8,780 | — | — | Form 4 ↗ |
| Sep 10, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Tax withholding | −4,230 | $144.81 | $613K | Form 4 ↗ |
| Sep 1, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Sold on the market10b5-1 plan | −15,000 | $148.64average | $2.2M | Form 4 ↗ |
| Aug 26, 2026 | Welters AnthonyDirector | Option exercise | +18,000 | $61.06average | $1.1M | Form 4 ↗ |
| Aug 26, 2026 | Welters AnthonyDirector | Sold on the market10b5-1 plan | −18,000 | $148.62average | $2.7M | Form 4 ↗ |
| Aug 20, 2026 | Bluestone JeffreyDirector | Option exercise | +5,000 | $67.04average | $335K | Form 4 ↗ |
| Aug 20, 2026 | Bluestone JeffreyDirector | Sold on the market10b5-1 plan | −5,000 | $145.02average | $725K | Form 4 ↗ |
| Aug 17, 2026 | Dickinson Andrew DCFO | Sold on the market10b5-1 plan | −3,000 | $138.36 | $415K | Form 4 ↗ |
| Aug 17, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Option exercise | +25,000 | $67.07average | $1.7M | Form 4 ↗ |
| Aug 17, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sold on the market10b5-1 plan | −28,000 | $137.64average | $3.9M | Form 4 ↗ |
| Aug 10, 2026 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Units vested | +6,002 | — | — | Form 4 ↗ |
| Aug 10, 2026 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Tax withholding | −2,908 | $133.06 | $387K | Form 4 ↗ |
| Aug 3, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Sold on the market10b5-1 plan | −15,000 | $130.31average | $2.0M | Form 4 ↗ |
| Jul 15, 2026 | Dickinson Andrew DCFO | Sold on the market10b5-1 plan | −3,000 | $129.93 | $390K | Form 4 ↗ |
| Jul 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sold on the market10b5-1 plan | −3,000 | $129.92 | $390K | Form 4 ↗ |
| Jul 1, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Sold on the market10b5-1 plan | −15,000 | $126.29average | $1.9M | Form 4 ↗ |
| Jun 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sold on the market10b5-1 plan | −3,000 | $123.92average | $372K | Form 4 ↗ |
| Jun 15, 2026 | Dickinson Andrew DCFO | Sold on the market10b5-1 plan | −3,000 | $125.40 | $376K | Form 4 ↗ |
| Jun 10, 2026 | Berger DietmarChief Medical Officer | Units vested | +533 | — | — | Form 4 ↗ |
| Jun 10, 2026 | Berger DietmarChief Medical Officer | Tax withholding | −263 | $121.48 | $31.9K | Form 4 ↗ |
| Jun 10, 2026 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Units vested | +589 | — | — | Form 4 ↗ |
| Jun 10, 2026 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Tax withholding | −283 | $121.48 | $34.4K | Form 4 ↗ |
| Jun 10, 2026 | Dickinson Andrew DCFO | Units vested | +2,796 | — | — | Form 4 ↗ |
| Jun 10, 2026 | Dickinson Andrew DCFO | Tax withholding | −1,341 | $121.48 | $163K | Form 4 ↗ |
| Jun 10, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Units vested | +2,796 | — | — | Form 4 ↗ |
| Jun 10, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Tax withholding | −1,341 | $121.48 | $163K | Form 4 ↗ |
| Jun 10, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Units vested | +8,779 | — | — | Form 4 ↗ |
| Jun 10, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Tax withholding | −4,213 | $121.48 | $512K | Form 4 ↗ |
| Jun 1, 2026 | O'Day Daniel PatrickChairman & CEO, Director | Sold on the market10b5-1 plan | −15,000 | $131.46average | $2.0M | Form 4 ↗ |
| May 26, 2026 | Gilead Sciences, INC.10% owner | Award | +471,698 | $26.50 | $12.5M | Form 4 ↗ |
| May 15, 2026 | Dickinson Andrew DCFO | Sold on the market10b5-1 plan | −3,000 | $132.27 | $397K | Form 4 ↗ |
| May 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Option exercise | +25,000 | $66.64 | $1.7M | Form 4 ↗ |
| May 15, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Sold on the market10b5-1 plan | −28,000 | $131.29average | $3.7M | Form 4 ↗ |
| Apr 30, 2026 | Bluestone JeffreyDirector | Award | +1,146 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Bluestone JeffreyDirector | AwardNon-qualified Stock Option (Right to Buy) | +4,884 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Barton Jacqueline KDirector | Award | +1,146 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Barton Jacqueline KDirector | AwardNon-qualified Stock Option (Right to Buy) | +4,884 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Horning SandraDirector | Award | +1,146 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Horning SandraDirector | AwardNon-qualified Stock Option (Right to Buy) | +4,884 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Love Ted WDirector | Award | +1,146 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Love Ted WDirector | AwardNon-qualified Stock Option (Right to Buy) | +4,884 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Rodriguez JavierDirector | Award | +1,146 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Rodriguez JavierDirector | AwardNon-qualified Stock Option (Right to Buy) | +4,884 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Welters AnthonyDirector | Award | +1,146 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Welters AnthonyDirector | AwardNon-qualified Stock Option (Right to Buy) | +4,884 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Manwani HarishDirector | Award | +1,146 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Manwani HarishDirector | Tax withholding | −224 | $130.84 | $29.3K | Form 4 ↗ |
| Apr 30, 2026 | Manwani HarishDirector | AwardNon-qualified Stock Option (Right to Buy) | +4,884 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Kramer Kelly A.Director | AwardRestricted Stock Unit | +1,146 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Kramer Kelly A.Director | AwardNon-qualified Stock Option (Right to Buy) | +4,884 | — | — | Form 4 ↗ |
SEC Form 4, public domain. The latest 40 of 83 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Beat the forecast in 4 of the last 4 quarters.
The stock's move is from the close before the report to the close after it.